A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
- Conditions
- cMET-dysregulated Advanced Solid Tumors
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02626234
- Locations
- πΊπΈ
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
π¬π§Novartis Investigative Site, Manchester, United Kingdom
πΊπΈEmory University School of Medicine/Winship Cancer Institute Phase 1 Working Group, Atlanta, Georgia, United States
A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)
- Conditions
- Chronic Urticaria
- Interventions
- Other: Non Interventional Study
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 497
- Registration Number
- NCT02626221
- Locations
- π΅πͺ
Novartis Investigative Site, San Martin de Porres, Lima, Peru
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT02625922
- Locations
- π¬π§
Novartis Investigative Site, Tyne And Wear, United Kingdom
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
- Conditions
- FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)Acute Myeloid Leukemia (AML) With
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02624570
- Locations
- πΊπΈ
City of Hope National Medical Center Department of Hematology & HCT, Duarte, California, United States
πΊπΈThe Jordan Research and Education Center ABSMC Comprehensive Cancer Ctr, Berkeley, California, United States
πΊπΈSt. Judes Medical Center, Fullerton, California, United States
Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT02624557
- Locations
- πΊπΈ
University of Miami / Clinical Research Services, Inc., Miami, Florida, United States
πΊπΈDaVita Clinical Research-Denver, Lakewood, Colorado, United States
πΊπΈDaVita Clinical Research, Minneapolis, Minnesota, United States
Safety and Efficacy Study of SOM230 s.c. in Cluster Headache
- Conditions
- Cluster Headache - Episodic and Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT02619617
- Locations
- π¬π§
Novartis Investigative Site, London, United Kingdom
Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT02607774
- Locations
- πΊπΈ
Novartis Investigative Site, Norfolk, Virginia, United States
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
- Conditions
- Advanced Malignancies
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 252
- Registration Number
- NCT02608268
- Locations
- πΊπΈ
Sidney Kimmel CCC At JH Sidney Kimmel CCC, Baltimore, Maryland, United States
πΊπΈDana Farber Cancer Institute DFCI - Brookline, Boston, Massachusetts, United States
πΊπΈUT M.D Anderson Cancer Center, Houston, Texas, United States
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
- Conditions
- MelanomaOther Solid TumorsNSCLCOvarian Cancer
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 142
- Registration Number
- NCT02607813
- Locations
- πΊπΈ
Massachusetts General Hospital MGH Cancer Center, Boston, Massachusetts, United States
π¨πNovartis Investigative Site, Zuerich, Switzerland
π³π±Medical Oncology, Erasmus MC, Rotterdam, Netherlands
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Drug: Investigator choice of chemotherapy
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT02605967
- Locations
- πΉπ
Novartis Investigative Site, Chiang Mai, Thailand
πΊπΈKarmanos Cancer Institute, Detroit, Michigan, United States
πΊπΈNorthwest Georgia Oncology Center NWGA Onc - Carrollton, Marietta, Georgia, United States